Physician profile
James Smith
NPI 1023078052
$42,651.26
in general payments reported to CMS, 2019-2025
24 companies · $320 in 2025
The $320 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $5,926 · 2022: $20K · 2023: $15K · 2024: $1,852 · 2025: $320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,750 · Consulting Fee: $5,063 · Food and Beverage: $4,680 · Travel and Lodging: $349 · Education: $97.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,750.00 |
| Consulting Fee | $5,063.00 |
| Food and Beverage | $4,680.41 |
| Travel and Lodging | $348.57 |
| Education | $97.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $34,089.41 | 2021-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $2,791.33 | 2021-2024 | Trintellix |
| Abbvie INC. | $1,210.41 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $926.44 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $873.79 | 2021-2025 | Rexulti, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $533.64 | 2021-2024 | Austedo Xr, Austedo |
| Alkermes, INC. | $467.78 | 2022-2024 | Lybalvi, Aristada, Vivitrol |
| Lundbeck LLC | $419.16 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Corium, LLC | $222.48 | 2021-2024 | Azstarys |
| Bausch Health US, LLC | $217.07 | 2021-2023 | Aplenzin, Wellbutrin |
| Janssen Pharmaceuticals, INC | $186.17 | 2022-2023 | Invega Sustenna, Spravato, Invega Trinza |
| Axsome Therapeutics, INC. | $144.14 | 2023-2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $109.35 | 2021 | |
| Tris Pharma INC | $96.76 | 2024-2025 | Dyanavel Xr, Onyda Xr |
| Noven Therapeutics, LLC | $68.54 | 2022-2023 | Xelstrym |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $62.99 | 2022-2024 | Jornay Pm |
| Biogen, INC. | $60.00 | 2022 | |
| Jazz Pharmaceuticals INC. | $41.67 | 2021 | |
| Almatica Pharma LLC | $31.69 | 2022-2024 | Loreev Xr |
| Idorsia Pharmaceuticals US INC | $29.22 | 2022-2023 | Quviviq |
| Medtronic, INC. | $19.44 | 2024 | Concertotm |
| Adlon Therapeutics L.P. | $18.94 | 2021 | |
| Vanda Pharmaceuticals INC. | $16.44 | 2022 | |
| Owp Pharmaceuticals, INC. | $14.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.